Biosimilars Market: Global Forecast to 2036

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 SEGMENTS CONSIDERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN BIOSIMILARS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3.1 BIOSIMILARS MARKET OVERVIEW
3.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS
3.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 BIOSIMILARS MARKET SHARE, BY INDICATION, 2026 VS. 2036 (%)

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Patent Expiry of Blockbuster Biologics
4.2.1.2 Healthcare Cost-Containment and Favorable Reimbursement Policies
4.2.1.3 Increasing Physician and Patient Acceptance of Biosimilars
4.2.1.4 Regulatory Harmonization and Faster Biosimilar Approval Pathways
4.2.2 RESTRAINTS
4.2.2.1 Price Erosion Due to Intense Biosimilar Competition
4.2.2.2 High Development and Manufacturing Costs
4.2.2.3 Regulatory Complexity Across Emerging Markets
4.2.2.4 Limited Physician Confidence in Certain Regions
4.2.3 OPPORTUNITIES
4.2.3.1 Next-Wave Patent Expiries of High-Value Biologics
4.2.3.2 Expansion into Emerging Markets
4.2.3.3 Interchangeability & Automatic Pharmacy Substitution
4.2.3.4 Government Incentives for Domestic Biologics Manufacturing
4.2.4 CHALLENGES
4.2.4.1 Intensifying Competition Among Biosimilar Manufacturers
4.2.4.2 Originator Lifecycle Management Strategies
4.2.4.3 Manufacturing Capacity & Supply Chain Complexity
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL BIOSIMILARS MARKET
5.2.4 TRENDS IN HEALTHCARE EXPENDITURE
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,BY KEY PLAYER, 2023-2025
5.6.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,BY REGION, 2023-2025
5.7 KEY CONFERENCES & EVENTS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT/FUNDING ACTIVITY
5.10 CASE STUDY ANALYSIS
5.11 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRY/REGION
5.11.4.1 North America
5.11.4.1.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES
5.12 PIPELINE ANALYSIS
5.12.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE
5.13 LIST OF KEY BIOLOGICS TO GO OFF-PATENT
5.14 LIST OF BIOSIMILARS MANUFACTURING FACILITIES, BY KEY PLAYER
5.15 MANUFACTURING FACILITY EXPANSION

6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 Advanced bioprocessing & manufacturing technologies
6.1.1.2 Analytical & characterization techniques
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 AI & ML
6.1.2.2 Lab automation & robotics
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Microbial fermentation
6.1.3.2 3D bioprinting & high-density cell culture
6.2 FUTURE APPLICATIONS
6.3 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET
6.3.1 TOP USE CASES AND MARKET POTENTIAL
6.3.1.1 Accelerated Drug Development and Reduced Costs
6.3.1.2 Enhanced Manufacturing and Quality Control
6.3.1.3 Smarter Commercialization and Regulatory Strategy
6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOSIMILARS MARKET
6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM ANDIMPACT ON MARKET PLAYERS
6.3.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOSIMILARS MARKET
6.4 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.2 REIMBURSEMENT SCENARIO ANALYSIS
7.2.1 INDUSTRY STANDARDS
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY

9.1 INTRODUCTION
9.2 MONOCLONAL ANTIBODIES
9.2.1 RITUXIMAB
9.2.1.1 Increasing cancer and autoimmune disease burden, coupled with expanding biosimilar competition, to support market growth
9.2.2 INFLIXIMAB
9.2.2.1 Loss of patent exclusivity to fuel adoption of Infliximab for treating autoimmune diseases
9.2.3 ADALIMUMAB
9.2.3.1 Cost-effectiveness and improved patient access to fuel segment growth
9.2.4 TRASTUZUMAB
9.2.4.1 Rising incidence of breast cancer to support market growth
9.2.5 PEMBROLIZUMAB
9.2.5.1 High-value oncology opportunity driven by Keytruda’s patent expiry and strong biosimilar pipeline
9.2.6 DUPILUMAB
9.2.6.1 Broad indication base and blockbuster sales make dupilumab high-value next-wave biosimilar opportunity
9.2.7 USTEKINUMAB
9.2.7.1 Highly competitive biosimilars market, with multiple products commercialized across major regions
9.2.8 RISANKIZUMAB
9.2.8.1 Rapidly growing Skyrizi sales and broad inflammatory-disease footprint make risankizumab major future biosimilar opportunity
9.2.9 DARATUMUMAB
9.2.9.1 High-value oncology franchise and expanding multiple myeloma use make daratumumab major future biosimilar opportunity
9.2.10 NIVOLUMAB
9.2.10.1 Large oncology revenue base and broad tumor coverage make nivolumab important future checkpoint
9.2.11 OTHER MONOCLONAL ANTIBODIES
9.3 GRANULOCYTE COLONY-STIMULATING FACTOR
9.3.1 MATURE COMMERCIALIZATION AND ESTABLISHED BIOSIMILAR ADOPTION MAKE G-CSF HIGH-VOLUME, PRICE-COMPETITIVE BIOSIMILAR SEGMENT
9.4 INSULIN
9.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH
9.5 ERYTHROPOIETIN
9.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH
9.6 RECOMBINANT HUMAN GROWTH HORMONE
9.6.1 RISING INCIDENCE OF GROWTH DEFICIENCY DISORDERS IN ADULTS AND CHILDREN TO PROPEL MARKET GROWTH
9.7 ETANERCEPT
9.7.1 APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS TO ACCELERATE MARKET EXPANSION
9.8 FOLLITROPIN
9.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TOSPUR MARKET GROWTH
9.9 TERIPARATIDE
9.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND
9.10 INTERFERONS
9.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASESTO SUPPORT MARKET GROWTH
9.11 ANTICOAGULANTS
9.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASESTO FUEL MARKET GROWTH
9.12 AFLIBERCEPT
9.12.1 LARGE OPHTHALMOLOGY MARKET AND RAPID BIOSIMILAR UPTAKE ARE MAKING AFLIBERCEPT KEY COMMERCIAL BIOSIMILAR SEGMENT
9.13 GLP-1 AGONIST
9.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH
9.14 OTHER DRUG CLASSES

10.1 INTRODUCTION
10.2 ONCOLOGY
10.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS FOR CANCER TO DRIVE MARKET
10.3 INFLAMMATORY & AUTOIMMUNE DISEASES
10.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS LEAD TO INCREASING INCIDENCES OF INFLAMMATORY AND AUTOIMMUNE DISEASES
10.4 CHRONIC DISEASES
10.4.1 HIGH BURDEN OF CVD WORLDWIDE TO DRIVE MARKET GROWTH
10.5 BLOOD DISORDERS
10.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
10.6 GROWTH HORMONE DEFICIENCY
10.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT OF GHD
10.7 INFECTIOUS DISEASES
10.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC
10.8 TYPE II DIABETES
10.8.1 RISING PREVALENCE OF DIABETES PROPELS MARKET GROWTH
10.9 OBESITY
10.9.1 DEVELOPMENT OF GLP-1 ANTAGONIST BIOSIMILARS PROPELS MARKET GROWTH
10.10 OTHER INDICATIONS

11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 US to dominate North American biosimilars market
11.2.2 CANADA
11.2.2.1 Favorable government initiatives to support market
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 Germany to dominate European biosimilars market
11.3.2 UK
11.3.2.1 Increasing adoption of biosimilars to boost market
11.3.3 FRANCE
11.3.3.1 Rising geriatric population to drive market growth
11.3.4 ITALY
11.3.4.1 Favorable government policies to propel adoption of biosimilars
11.3.5 SPAIN
11.3.5.1 Favorable patient incentives to promote biosimilar use
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.1.1 China to register fastest growth in Asia Pacific market
11.4.2 JAPAN
11.4.2.1 Large geriatric population to drive market growth
11.4.3 INDIA
11.4.3.1 Increasing biosimilar launches and approvals to support market growth
11.4.4 SOUTH KOREA
11.4.4.1 Favorable government initiatives to support growth
11.4.5 AUSTRALIA
11.4.5.1 Favorable regulatory changes and increasing disease incidence to propel growth
11.4.6 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.1.1 Increased government investments in pharmaceuticalR&D to drive market
11.5.2 MEXICO
11.5.2.1 Rising demand for chronic disease treatment to support market growth
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 GCC COUNTRIES
11.6.1.1 Saudi Arabia
11.6.1.1.1 Centralized procurement, localization policies, and increasingly biosimilar-supportive regulatory framework to accelerate biosimilar adoption in Saudi Arabia
11.6.1.2 UAE
11.6.1.2.1 Rapid expansion of advanced healthcare infrastructure combined with payer pressure to reduce biologic treatment costs is strengthening commercial case for biosimilars in UAE
11.6.1.3 Rest of GCC
11.6.2 REST OF MIDDLE EAST
11.7 AFRICA

12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2024-2026
12.3 REVENUE ANALYSIS, 2023-2025
12.4 MARKET SHARE ANALYSIS, 2025
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPETITIVE BENCHMARKING OF TOP PLAYERS
12.6.1 COMPANY FOOTPRINT
12.6.2 REGION FOOTPRINT
12.6.3 DRUG CLASS FOOTPRINT
12.6.4 INDICATION FOOTPRINT
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
12.8 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
12.9 VALUATION AND FINANCIAL METRICS OF BIOSIMILAR VENDORS
12.9.1 FINANCIAL METRICS
12.9.2 COMPANY VALUATION
12.10 BRAND/PRODUCT COMPARISON
12.11 COMPETITIVE SCENARIO
12.11.1 PRODUCT APPROVALS
12.11.2 DEALS
12.11.3 EXPANSIONS

13.1 KEY PLAYERS
13.1.1 SANDOZ GROUP AG
13.1.1.1 Products offered
13.1.1.2 Products in pipeline
13.1.1.3 Recent developments
13.1.1.3.1 Product launches and approvals
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.3.4 Other developments
13.1.1.4 Analyst's view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 AMGEN INC.
13.1.2.1 Products offered
13.1.2.2 Products in pipeline
13.1.2.3 Recent developments
13.1.2.3.1 Product launches and approvals
13.1.2.3.2 Deals
13.1.2.3.3 Expansions
13.1.2.4 Analyst's view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 CELLTRION INC.
13.1.3.1 Products offered
13.1.3.2 Recent developments
13.1.3.2.1 Product launches and approvals
13.1.3.2.2 Deals
13.1.3.2.3 Expansions
13.1.3.3 Analyst's view
13.1.3.3.1 Key strengths
13.1.3.3.2 Strategic choices
13.1.3.3.3 Weaknesses & competitive threats
13.1.4 PFIZER INC.
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product approvals
13.1.4.3.2 Deals
13.1.4.4 Analyst's view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 BIOCON
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product approvals
13.1.5.3.2 Deals
13.1.5.3.3 Other developments
13.1.5.4 Analyst's view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 DR. REDDY’S LABORATORIES LTD.
13.1.6.1 Products offered
13.1.6.2 Recent developments
13.1.6.2.1 Product launches
13.1.6.2.2 Deals
13.1.6.2.3 Other developments
13.1.7 ELI LILLY AND COMPANY
13.1.7.1 Products offered
13.1.7.2 Recent developments
13.1.7.2.1 Product launches
13.1.7.2.2 Deals
13.1.7.2.3 Expansions
13.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.1.8.1 Products offered
13.1.8.2 Recent developments
13.1.8.2.1 Product launches and approvals
13.1.8.2.2 Deals
13.1.8.2.3 Other developments
13.1.9 FRESENIUS KABI AG
13.1.9.1 Products offered
13.1.9.2 Recent developments
13.1.9.2.1 Product Launches and Approvals
13.1.9.2.2 Deals
13.1.9.2.3 Other developments
13.1.10 STADA ARZNEIMITTEL AG
13.1.10.1 Products offered
13.1.10.2 Recent developments
13.1.10.2.1 Product launches/Approvals
13.1.10.2.2 Deals
13.1.10.2.3 Expansions
13.1.10.2.4 Other developments
13.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.11.1 Products offered
13.1.11.2 Recent developments
13.1.11.2.1 Product approvals
13.1.11.2.2 Deals
13.1.11.2.3 Expansions
13.1.12 SAMSUNG BIOEPIS HOLDINGS CO., LTD.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Product Launches and Approvals
13.1.12.3.2 Deals
13.1.13 AMNEAL PHARMACEUTICALS LLC
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Product approvals
13.1.13.3.2 Deals
13.1.13.3.3 Other developments
13.1.14 BIO THERA SOLUTIONS
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.14.3 Recent developments
13.1.14.3.1 Product approvals
13.1.14.3.2 Deals
13.1.15 APROGEN
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product approvals
13.1.15.4 Products in pipeline
13.1.16 SHANGHAI HENLIUS BIOTECH, INC.
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.16.3 Products in pipeline
13.1.16.4 Recent developments
13.1.16.4.1 Product approvals
13.1.16.4.2 Deals
13.1.16.4.3 Other developments
13.1.17 ALVOTECH
13.1.17.1 Business overview
13.1.17.2 Products offered
13.1.17.3 Products in pipeline
13.1.17.4 Recent developments
13.1.17.4.1 Product approvals
13.1.17.4.2 Deals
13.2 OTHER PLAYERS
13.2.1 AMEGA BIOTECH
13.2.2 BIOCAD
13.2.3 PROBIOMED S.A. DE C.V.
13.2.4 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
13.2.5 POLPHARMA BIOLOGICS GROUP
13.2.6 NEUCLONE
13.2.7 XENTRIA
13.2.8 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
13.2.9 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.
13.2.10 CURATEQ BIOLOGICS PVT. LTD.
13.2.11 XBRANE BIOPHARMA AB
13.2.12 FORMYCON AG
13.2.13 SAM CHUN DANG PHARM. CO., LTD.
13.2.14 PRESTIGE BIOPHARMA
13.2.15 BIOEQ AG

14.1 RESEARCH DATA
14.1.1 SECONDARY DATA
14.1.1.1 Key data from secondary sources
14.1.2 PRIMARY DATA
14.2 MARKET ESTIMATION METHODOLOGY
14.2.1 GLOBAL MARKET ESTIMATION
14.2.2 INSIGHTS OF PRIMARY EXPERTS
14.2.3 SEGMENTAL MARKET SIZE ESTIMATION
14.3 MARKET GROWTH RATE PROJECTIONS
14.4 MARKET BREAKDOWN AND DATA TRIANGULATION
14.5 RESEARCH ASSUMPTIONS
14.6 RESEARCH LIMITATIONS
14.7 RISK ANALYSIS

15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS

TABLE 1 BIOSIMILARS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 BIOSIMILARS MARKET: IMPACT ANALYSIS
TABLE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION,2023-2030 (USD MILLION)
TABLE 4 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 HEALTH EXPENDITURE AND FINANCING, 2015-2024 (IN PERCENTAGE OF GDP)
TABLE 6 BIOSIMILARS MARKET: ROLE IN ECOSYSTEM
TABLE 7 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,BY KEY PLAYER, 2023-2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION,2023-2025 (USD)
TABLE 9 BIOSIMILARS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
TABLE 10 PORTFOLIO SCALE & COMMERCIALIZATION
TABLE 11 PAYER ACCESS & MARKET PENETRATION
TABLE 12 PRODUCT DIFFERENTIATION & INTERCHANGEABILITY
TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 BIOSIMILARS MARKET: PRODUCTS IN CLINICAL PIPELINE
TABLE 15 BIOSIMILARS MARKET: LIST OF KEY BIOLOGICS TO GO OFF-PATENT, 2026-2036
TABLE 16 BIOSIMILARS MARKET: LIST OF BIOSIMILARS MANUFACTURING FACILITIES(IN-HOUSE) BY KEY PLAYER
TABLE 17 BIOSIMILARS MARKET: LIST OF KEY MANUFACTURING FACILITY EXPANSION
TABLE 18 KEY COMPANIES TECHNOLOGY/PRODUCT ROADMAP — BIOSIMILARS MARKET
TABLE 19 CASE STUDIES OF AI IMPLEMENTATION IN BIOSIMILARS MARKET
TABLE 20 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOSIMILARS MARKET
TABLE 21 KEY SUCCESS STORIES WITH RESPECT OT REAL WORLD APPLICATION IN BIOSIMILARS MARKET
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 26 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REGULATORY FRAMEWORK
TABLE 27 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REIMBURSEMENT FRAMEWORK
TABLE 28 US: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED BIOSIMILARS,2025-2026
TABLE 29 US: REIMBURSEMENT CODES FOR BIOSIMILAR PRODUCTS
TABLE 30 EUROPE: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHEDBIOSIMILARS, 2025-2026
TABLE 31 KEY INDUSTRY STANDARDS FOR BIOSIMILARS MARKET
TABLE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS (%)
TABLE 33 KEY BUYING CRITERIA, BY END USER
TABLE 34 UNMET NEEDS ACROSS DIFFERENT END USERS IN BIOSIMILARS MARKET
TABLE 35 BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 36 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 37 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,2024-2036 (USD MILLION)
TABLE 38 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 39 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 40 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 41 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 42 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY REGION, 2024-2036 (USD MILLION)
TABLE 43 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 44 RITUXIMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 45 NORTH AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 46 EUROPE: RITUXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 47 ASIA PACIFIC: RITUXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 48 LATIN AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 49 MIDDLE EAST: RITUXIMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 50 GCC COUNTRIES: RITUXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 51 INFLIXIMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 52 NORTH AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 53 EUROPE: INFLIXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 54 ASIA PACIFIC: INFLIXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 55 LATIN AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 56 MIDDLE EAST: INFLIXIMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 57 GCC COUNTRIES: INFLIXIMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 58 ADALIMUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 59 NORTH AMERICA: ADALIMUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 60 EUROPE: ADALIMUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 61 ASIA PACIFIC: ADALIMUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 62 LATIN AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 63 MIDDLE EAST: ADALIMUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 64 GCC COUNTRIES: ADALIMUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 65 TRASTUZUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 66 NORTH AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 67 EUROPE: TRASTUZUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 68 ASIA PACIFIC: TRASTUZUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 69 LATIN AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 70 MIDDLE EAST: TRASTUZUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 71 GCC COUNTRIES: TRASTUZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 72 PEMBROLIZUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 73 NORTH AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 74 EUROPE: PEMBROLIZUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 75 ASIA PACIFIC: PEMBROLIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 76 LATIN AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 77 MIDDLE EAST: PEMBROLIZUMAB MARKET, BY REGION,2024-2036 (USD MILLION)
TABLE 78 GCC COUNTRIES: PEMBROLIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 79 DUPILUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 80 NORTH AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 81 EUROPE: DUPILUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 82 ASIA PACIFIC: DUPILUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 83 LATIN AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 84 MIDDLE EAST: DUPILUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 85 GCC COUNTRIES: DUPILUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 86 USTEKINUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 87 NORTH AMERICA: USTEKINUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 88 EUROPE: USTEKINUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 89 ASIA PACIFIC: USTEKINUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 90 LATIN AMERICA: USTEKINUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 91 MIDDLE EAST: USTEKINUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 92 GCC COUNTRIES: USTEKINUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 93 RISANKIZUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 94 NORTH AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 95 EUROPE: RISANKIZUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 96 ASIA PACIFIC: RISANKIZUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 97 LATIN AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 98 MIDDLE EAST: RISANKIZUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 99 GCC COUNTRIES: RISANKIZUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 100 DARATUMUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 101 NORTH AMERICA: DARATUMUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 102 EUROPE: DARATUMUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 103 ASIA PACIFIC: DARATUMUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 104 LATIN AMERICA: DARATUMUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 105 MIDDLE EAST: DARATUMUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 106 GCC COUNTRIES: DARATUMUMAB MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 107 NIVOLUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 108 NORTH AMERICA: NIVOLUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 109 EUROPE: NIVOLUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 110 ASIA PACIFIC: NIVOLUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 111 LATIN AMERICA: NIVOLUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 112 MIDDLE EAST: NIVOLUMAB MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 113 GCC COUNTRIES: NIVOLUMAB MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 114 OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,2024-2036 (USD MILLION)
TABLE 115 NORTH AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 116 EUROPE: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 117 ASIA PACIFIC: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 118 LATIN AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 119 MIDDLE EAST: OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,2024-2036 (USD MILLION)
TABLE 120 GCC COUNTRIES: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 121 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
TABLE 122 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,BY REGION, 2024-2036 (USD MILLION)
TABLE 123 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 124 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 125 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 126 LATIN AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 127 MIDDLE EAST: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 128 GCC COUNTRIES: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 129 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2024-2036 (USD MILLION)
TABLE 130 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 131 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 132 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 133 LATIN AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 134 MIDDLE EAST: BIOSIMILARS MARKET FOR INSULIN, BY REGION,2024-2036 (USD MILLION)
TABLE 135 GCC COUNTRIES: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 136 LIST OF KEY APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 137 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,2024-2036 (USD MILLION)
TABLE 138 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 139 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 140 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 141 LATIN AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 142 MIDDLE EAST: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,2024-2036 (USD MILLION)
TABLE 143 GCC COUNTRIES: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 144 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,BY REGION, 2024-2036 (USD MILLION)
TABLE 145 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 146 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 147 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 148 LATIN AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 149 MIDDLE EAST: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2024-2036 (USD MILLION)
TABLE 150 GCC COUNTRIES: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 151 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2024-2036 (USD MILLION)
TABLE 152 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 153 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 154 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 155 LATIN AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 156 MIDDLE EAST: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION,2024-2036 (USD MILLION)
TABLE 157 GCC COUNTRIES: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 158 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2024-2036 (USD MILLION)
TABLE 159 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 160 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 161 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 162 LATIN AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 163 MIDDLE EAST: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION,2024-2036 (USD MILLION)
TABLE 164 GCC COUNTRIES: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 165 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,2024-2036 (USD MILLION)
TABLE 166 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 167 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 168 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 169 LATIN AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 170 MIDDLE EAST: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,2024-2036 (USD MILLION)
TABLE 171 GCC COUNTRIES: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 172 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,2024-2036 (USD MILLION)
TABLE 173 NORTH AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 174 EUROPE: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 175 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 176 LATIN AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 177 MIDDLE EAST: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,2024-2036 (USD MILLION)
TABLE 178 GCC COUNTRIES: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 179 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,2024-2036 (USD MILLION)
TABLE 180 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 181 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 182 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 183 LATIN AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 184 MIDDLE EAST: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,2024-2036 (USD MILLION)
TABLE 185 GCC COUNTRIES: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 186 BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 2024-2036 (USD MILLION)
TABLE 187 NORTH AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 188 EUROPE: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 189 ASIA PACIFIC: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 190 LATIN AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 191 MIDDLE EAST: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION,2024-2036 (USD MILLION)
TABLE 192 GCC COUNTRIES: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 193 BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY REGION,2024-2036 (USD MILLION)
TABLE 194 NORTH AMERICA: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 195 EUROPE: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 196 ASIA PACIFIC: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 197 LATIN AMERICA: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 198 MIDDLE EAST: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY REGION,2024-2036 (USD MILLION)
TABLE 199 GCC COUNTRIES: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 200 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION,2024-2036 (USD MILLION)
TABLE 201 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 202 EUROPE: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 203 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 204 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 205 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2024-2036 (USD MILLION)
TABLE 206 GCC COUNTRIES: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 207 BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 208 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2024-2036 (USD MILLION)
TABLE 209 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 210 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 211 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 212 LATIN AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 213 MIDDLE EAST: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION,2024-2036 (USD MILLION)
TABLE 214 GCC COUNTRIES: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 215 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES,BY REGION, 2024-2036 (USD MILLION)
TABLE 216 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 217 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 218 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 219 LATIN AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 220 MIDDLE EAST: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024-2036 (USD MILLION)
TABLE 221 GCC COUNTRIES: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 222 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,2024-2036 (USD MILLION)
TABLE 223 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 224 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 225 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 226 LATIN AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 227 MIDDLE EAST: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,2024-2036 (USD MILLION)
TABLE 228 GCC COUNTRIES: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 229 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,2024-2036 (USD MILLION)
TABLE 230 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 231 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 232 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 233 LATIN AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 234 MIDDLE EAST: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,2024-2036 (USD MILLION)
TABLE 235 GCC COUNTRIES: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 236 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION,2024-2036 (USD MILLION)
TABLE 237 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 238 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 239 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 240 LATIN AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 241 MIDDLE EAST: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY REGION, 2024-2036 (USD MILLION)
TABLE 242 GCC COUNTRIES: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 243 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,2024-2036 (USD MILLION)
TABLE 244 NORTH AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 245 EUROPE: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 246 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 247 LATIN AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 248 MIDDLE EAST: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2036 (USD MILLION)
TABLE 249 GCC COUNTRIES: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 250 BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,2024-2036 (USD MILLION)
TABLE 251 NORTH AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES,BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 252 EUROPE: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 253 ASIA PACIFIC: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 254 LATIN AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 255 MIDDLE EAST: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,2024-2036 (USD MILLION)
TABLE 256 GCC COUNTRIES: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 257 BIOSIMILARS MARKET FOR OBESITY, BY REGION, 2024-2036 (USD MILLION)
TABLE 258 NORTH AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 259 EUROPE: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 260 ASIA PACIFIC: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 261 LATIN AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 262 MIDDLE EAST: BIOSIMILARS MARKET FOR OBESITY, BY REGION,2024-2036 (USD MILLION)
TABLE 263 GCC COUNTRIES: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 264 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION,2024-2036 (USD MILLION)
TABLE 265 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 266 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 267 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 268 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 269 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2036 (USD MILLION)
TABLE 270 GCC COUNTRIES: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 271 BIOSIMILARS MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 272 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 273 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 274 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 275 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 276 US: LIST OF APPROVED BIOSIMILARS (2023-2026)
TABLE 277 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 278 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 279 US: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 280 CANADA: LIST OF APPROVED BIOSIMILARS (2023-2026)
TABLE 281 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 282 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 283 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 284 EUROPE: LIST OF APPROVED BIOSIMILARS (2023-2026)
TABLE 285 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 286 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 287 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 288 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 289 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 290 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 291 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 292 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 293 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 294 UK: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 295 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 296 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 297 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 298 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 299 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 300 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 301 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 302 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 303 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 304 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 305 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 306 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 307 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 308 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 309 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 310 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 311 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 312 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 313 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 314 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 315 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 316 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 317 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 318 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 319 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 320 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 321 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 322 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 323 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 324 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 325 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 326 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 327 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 329 LATIN AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2024-2036 (USD MILLION)
TABLE 330 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 331 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 332 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 333 BRAZIL: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 334 BRAZIL: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 335 BRAZIL: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 336 MEXICO: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 337 MEXICO: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 338 MEXICO: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 339 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 340 REST OF LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 341 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 342 MIDDLE EAST: BIOSIMILARS MARKET, BY REGION, 2024-2036 (USD MILLION)
TABLE 343 MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 344 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 345 MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 346 GCC COUNTRIES: BIOSIMILARS MARKET, BY COUNTRY,2024-2036 (USD MILLION)
TABLE 347 GCC COUNTRIES: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 348 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 349 GCC COUNTRIES: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 350 SAUDI ARABIA: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 351 SAUDI ARABIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 352 SAUDI ARABIA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 353 UAE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 354 UAE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 355 UAE: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 356 REST OF GCC: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 357 REST OF GCC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024-2036 (USD MILLION)
TABLE 358 REST OF GCC: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 359 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,2024-2036 (USD MILLION)
TABLE 360 REST OF MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,BY TYPE, 2024-2036 (USD MILLION)
TABLE 361 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION,2024-2036 (USD MILLION)
TABLE 362 AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024-2036 (USD MILLION)
TABLE 363 AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,2024-2036 (USD MILLION)
TABLE 364 AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2024-2036 (USD MILLION)
TABLE 365 STRATEGIES DEPLOYED BY KEY PLAYERS
TABLE 366 BIOSIMILARS MARKET: DEGREE OF COMPETITION
TABLE 367 BIOSIMILARS MARKET: REGIONAL FOOTPRINT
TABLE 368 BIOSIMILARS MARKET: DRUG CLASS FOOTPRINT
TABLE 369 BIOSIMILARS MARKET: INDICATION FOOTPRINT
TABLE 370 BIOSIMILARS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 371 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2025
TABLE 372 BIOSIMILARS MARKET: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 373 BIOSIMILARS MARKET: DEALS, JANUARY 2023-AUGUST 2026
TABLE 374 BIOSIMILARS MARKET: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 375 SANDOZ GROUP AG: COMPANY OVERVIEW
TABLE 376 SANDOZ GROUP AG: PRODUCTS OFFERED
TABLE 377 SANDOZ GROUP AG: PRODUCTS IN PIPELINE
TABLE 378 SANDOZ GROUP AG: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 379 SANDOZ GROUP AG: DEALS, JANUARY 2023-AUGUST 2026
TABLE 380 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 381 SANDOZ GROUP AG: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
TABLE 382 AMGEN INC.: COMPANY OVERVIEW
TABLE 383 AMGEN INC.: PRODUCTS OFFERED
TABLE 384 AMGEN INC.: PRODUCTS IN PIPELINE
TABLE 385 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 386 AMGEN INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 387 AMGEN INC.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 388 CELLTRION INC.: COMPANY OVERVIEW
TABLE 389 CELLTRION INC.: PRODUCTS OFFERED
TABLE 390 CELLTRION INC.: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 391 CELLTRION INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 392 CELLTRION INC.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 393 PFIZER INC.: COMPANY OVERVIEW
TABLE 394 PFIZER INC.: PRODUCTS OFFERED
TABLE 395 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 396 PFIZER INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 397 BIOCON: COMPANY OVERVIEW
TABLE 398 BIOCON: PRODUCTS OFFERED
TABLE 399 BIOCON: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 400 BIOCON: DEALS, JANUARY 2023-AUGUST 2026
TABLE 401 BIOCON: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
TABLE 402 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
TABLE 403 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED
TABLE 404 DR. REDDY’S LABORATORIES LTD.: PRODUCT LAUNCHES,JANUARY 2023-AUGUST 2026
TABLE 405 DR. REDDY’S LABORATORIES LTD.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 406 DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS,JANUARY 2023-AUGUST 2026
TABLE 407 ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 408 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 409 ELI LILLY AND COMPANY: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 410 ELI LILLY AND COMPANY: DEALS, JANUARY 2023-AUGUST 2026
TABLE 411 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 412 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 413 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 414 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 415 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 416 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS,JANUARY 2023-AUGUST 2026
TABLE 417 FRESENIUS KABI AG: COMPANY OVERVIEW
TABLE 418 FRESENIUS KABI AG.: PRODUCTS OFFERED
TABLE 419 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 420 FRESENIUS KABI AG: DEALS, JANUARY 2023-AUGUST 2026
TABLE 421 FRESENIUS KABI AG: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
TABLE 422 STADA ARZNEIMITTEL AG: COMPANY OVERVIEW
TABLE 423 STADA ARZNEIMITTEL AG: PRODUCTS OFFERED
TABLE 424 STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES AND APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 425 STADA ARZNEIMITTEL AG: DEALS, JANUARY 2023-AUGUST 2026
TABLE 426 STADA ARZNEIMITTEL AG: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 427 STADA ARZNEIMITTEL AG: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
TABLE 428 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 429 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 430 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 431 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,JANUARY 2023-AUGUST 2026
TABLE 432 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,JANUARY 2023-AUGUST 2026
TABLE 433 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: COMPANY OVERVIEW
TABLE 434 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: PRODUCTS OFFERED
TABLE 435 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 436 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 437 AMNEAL PHARMACEUTICALS LLC: COMPANY OVERVIEW
TABLE 438 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED
TABLE 439 AMNEAL PHARMACEUTICALS LLC: PRODUCT APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 440 AMNEAL PHARMACEUTICALS INC: DEALS, JANUARY 2023-AUGUST 2026
TABLE 441 AMNEAL PHARMACEUTICALS INC: OTHER DEVELOPMENTS,JANUARY 2023-AUGUST 2026
TABLE 442 BIO THERA SOLUTIONS: COMPANY OVERVIEW
TABLE 443 BIO THERA SOLUTIONS: PRODUCTS OFFERED
TABLE 444 BIO THERA SOLUTIONS: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 445 BIO THERA SOLUTIONS: DEALS, JANUARY 2023-AUGUST 2026
TABLE 446 APROGEN: COMPANY OVERVIEW
TABLE 447 APROGEN: PRODUCTS OFFERED
TABLE 448 APROGEN: PRODUCT DEVELOPMENTS, JANUARY 2023-AUGUST 2026
TABLE 449 APROGEN: PRODUCTS IN PIPELINE
TABLE 450 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
TABLE 451 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCTS OFFERED
TABLE 452 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCTS IN PIPELINE
TABLE 453 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT APPROVALS,JANUARY 2023-AUGUST 2026
TABLE 454 SHANGHAI HENLIUS BIOTECH, INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 455 SHANGHAI HENLIUS BIOTECH, INC.: OTHER DEVELOPMENTS,JANUARY 2023-AUGUST 2026
TABLE 456 ALVOTECH: COMPANY OVERVIEW
TABLE 457 ALVOTECH: PRODUCTS OFFERED
TABLE 458 ALVOTECH: PRODUCTS IN PIPELINE
TABLE 459 ALVOTECH: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
TABLE 460 ALVOTECH: DEALS, JANUARY 2023-AUGUST 2026
TABLE 461 AMEGA BIOTECH: COMPANY OVERVIEW
TABLE 462 BIOCAD: COMPANY OVERVIEW
TABLE 463 PROBIOMED S.A. DE C.V.: COMPANY OVERVIEW
TABLE 464 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.: COMPANY OVERVIEW
TABLE 465 POLPHARMA BIOLOGICS GROUP: COMPANY OVERVIEW
TABLE 466 NEUCLONE: COMPANY OVERVIEW
TABLE 467 XENTRIA: COMPANY OVERVIEW
TABLE 468 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC: COMPANY OVERVIEW
TABLE 469 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.: COMPANY OVERVIEW
TABLE 470 CURATEQ BIOLOGICS PVT. LTD.: COMPANY OVERVIEW
TABLE 471 XBRANE BIOPHARMA AB: COMPANY OVERVIEW
TABLE 472 FORMYCON AG: COMPANY OVERVIEW
TABLE 473 SAM CHUN DANG PHARM. CO., LTD.: COMPANY OVERVIEW
TABLE 474 PRESTIGE BIOPHARMA: COMPANY OVERVIEW
TABLE 475 BIOEQ AG: COMPANY OVERVIEW
TABLE 476 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

FIGURE 1 BIOSIMILARS MARKET: SEGMENTS CONSIDERED
FIGURE 2 BIOSIMILARS MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL BIOSIMILARS MARKET, 2024-2036
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET,2024-2036
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOSIMILARS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOSIMILARS MARKET, 2026-2036
FIGURE 8 MIDDLE EAST TO REGISTER HIGHEST CAGR IN BIOSIMILARS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 APPROVALS OF BIOSIMILARS TO DRIVE MARKET GROWTH
FIGURE 10 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF BIOSIMILARS MARKET IN NORTH AMERICA IN 2025
FIGURE 11 MEXICO LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL BIOSIMILARS MARKET DURING FORECAST PERIOD
FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 BIOSIMILARS MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 BIOSIMILARS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 17 BIOSIMILARS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, 2023-2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION,2023-2025 (USD)
FIGURE 20 BIOSIMILARS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 22 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS
FIGURE 24 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER
FIGURE 25 EUROPE: BIOSIMILARS MARKET SNAPSHOT
FIGURE 26 MIDDLE EAST: BIOSIMILARS MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2023-2025 (USD MILLION)
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 29 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 30 BIOSIMILARS MARKET: COMPANY FOOTPRINT
FIGURE 31 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 32 EV/EBITDA OF KEY VENDORS
FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETAOF KEY VENDORS
FIGURE 34 BIOSIMILARS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 35 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025)
FIGURE 36 AMGEN INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 CELLTRION INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 BIOCON: COMPANY SNAPSHOT (2025)
FIGURE 40 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025)
FIGURE 41 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025)
FIGURE 43 FRESENIUS KABI AG.: COMPANY SNAPSHOT (2025)
FIGURE 44 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2025)
FIGURE 45 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
FIGURE 46 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 47 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2025)
FIGURE 48 BIO THERA SOLUTIONS: COMPANY SNAPSHOT (2025)
FIGURE 49 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY SNAPSHOT (2025)
FIGURE 50 ALVOTECH: COMPANY SNAPSHOT (2025)
FIGURE 51 RESEARCH DESIGN
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BIOSIMILARS MARKET
FIGURE 53 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 54 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUEANALYSIS-BASED ESTIMATION), 2025
FIGURE 55 ILLUSTRATIVE EXAMPLE OF SANDOZ GROUP AG (SWITZERLAND):REVENUE SHARE ANALYSIS (2025)
FIGURE 56 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 57 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 58 BIOSIMILARS MARKET: CAGR PROJECTIONS
FIGURE 59 DATA TRIANGULATION METHODOLOGY